Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SPRBthis companySpruce Biosciences, Inc.	$47.91	-1.71×	1.57×	0×	-0.48×	38.7%	0.0%	0.0%	0.0%	-91.7%	-84.4%	-49.9%	0.02×	1.24×	-405.7×	5.17×	0.0%	2	-0.85	2	B-
CUECue Biopharma, Inc.	$19.03	-1.09×	1.09×	1.05×	-0.24×	-850.1%	100.0%	-96.6%	-96.9%	-100.6%	-86.6%	-75.6%	0.16×	0.93×	-74.29×	2.74×	0.0%	2	-30.14	1	D+
EQEquillium, Inc.	$1.59	-3.97×	4.98×	0×	-5.06×	-77.1%	0.0%	0.0%	0.0%	-78.3%	-83.3%	-16.0%	0.03×	1.33×	0×	10.32×	0.0%	1	14.51	2	C
HOWLWerewolf Therapeutics, Inc.	$1.02	-0.48×	1.18×	0×	0.36×	-2.6%	0.0%	0.0%	0.0%	-245.2%	-173.4%	-206.8%	0.38×	0.9×	-11.5×	1.62×	0.0%	4	-26.12	2	C+
NRXPNRx Pharmaceuticals, Inc.	$2.42	-2.02×	-3.64×	47.35×	-1.83×	-67.8%	58.8%	-1324.4%	-2336.5%	179.6%	106.0%	-24.3%	-0.04×	0.26×	-24.18×	0.31×	0.0%	4	-13.9	2	C+
OSTXOS Therapies Incorporated	$0.91	-1.43×	-6.72×	0×	-1.43×	-125.9%	0.0%	0.0%	0.0%	471.7%	582.9%	-34767.1%	0×	0.01×	0×	0.03×	0.0%	1	-25.65	2	C
Peer median	—	-1.43×	1.09×	0×	-1.43×	-77.1%	0.0%	0.0%	0.0%	-78.3%	-83.3%	-75.6%	0.03×	0.9×	-11.5×	1.62×	0.0%	2	-25.65	2	—